MannkindLogoStackedPreferd.jpg
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
June 16, 2021 06:15 ET | MannKind
Tyvaso DPI includes the second compound formulated with MannKind’s Technosphere® technology to be reviewed by the FDAFDA review expected to be complete in October 2021Hiring expansion underway at...
MannkindLogoStackedPreferd.jpg
MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases
June 10, 2021 06:15 ET | MannKind
MannKind will conduct formulation and preclinical studies of a new chemical entity owned by ThironaIn addition, MannKind purchased a convertible note issued by ThironaWESTLAKE VILLAGE, Calif. and...
MannkindLogoStackedPreferd.jpg
MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference
June 08, 2021 17:00 ET | MannKind
WESTLAKE VILLAGE, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
May 13, 2021 09:00 ET | MannKind
Daly to drive bold “Tired of Pricks?” design for Ed Carpenter Racingat GMR Grand Prix on May 15 at Indianapolis Motor Speedway Indiana native to share personal journey and raise awarenessabout...
MannkindLogoStackedPreferd.jpg
MannKind Corporation Reports 2021 First Quarter Financial Results
May 12, 2021 16:00 ET | MannKind
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million; +7% vs. 1Q 2020Received $230.0 million gross proceeds from 2.5% senior convertible notes$278.3 million of Cash,...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference
May 11, 2021 09:00 ET | MannKind
WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021
May 05, 2021 09:00 ET | MannKind
WESTLAKE VILLAGE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 first quarter financial results and its management will host a conference call to...
MannkindLogoStackedPreferd.jpg
MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
April 26, 2021 09:00 ET | MannKind
Paid Off Mann Group Non-Convertible Note of $35.1 Million in Principal plus $4.4 Million in Accrued InterestPrepaid $10.0 Million Owed Under MidCap Credit Facility and Increased Borrowings Available...
MannkindLogoStackedPreferd.jpg
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
April 19, 2021 06:00 ET | MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., April 19, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the...
MannkindLogoStackedPreferd.jpg
MannKind Announces Closing of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes
March 16, 2021 09:00 ET | MannKind
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal...